Risk evaluation and mitigation strategies (REMS) are designed and implemented during the commercialization of a pharmaceutical product to ensure an acceptable risk-to-benefit ratio for products that are known to exhibit specific risks. The U.S. Food and Drug Administration (FDA) determines if a REMS program is necessary.
PPD has a full range of capabilities and extensive experience supporting REMS programs for clients, including:
Our risk management team works in a matrix approach with departments across PPD. Experts in epidemiology, registries and observational studies, regulatory affairs, pharmacovigilance and call center operations provide support to REMS programs.
PPD’s integrated REMS technology platform simplifies the complex logistics of program management. Using Microsoft® Amalga™ and HealthVault™ technologies, sponsors can maintain control and a real-time view of all REMS components through a single dashboard. Doctors, patients and other stakeholders can access REMS programs and tools simultaneously via the platform’s customizable, user-friendly external interfaces.
PPD’s REMS technology platform is a single point for comprehensive risk management:
PPD has a broad range of experience designing, executing and managing REMS products and programs. We have designed a proven process to develop FDA-approved risk management tools, evaluation tools and methodologies, and patient and health care provider education and awareness tools. Our extensive experience in integrating REMS programs into product commercialization plans enables us to deliver solutions to our clients quickly and efficiently.
PPD understands and continually monitors regulatory, legislative, and market involving product safety and benefit-risk balance. We use our comprehensive understanding of the issues to provide REMS programs that address all aspects of risk management.